Sanara MedTech

SMTI

Market cap $176M

Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone

FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 before the U.S. financial markets open. The Company will host a conference call and webcast on March 24, 2026 at 8:00 a.m.

FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time.

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.

Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced that its BIASURGE® Advanced Surgical Solution (“BIASURGE”) product has received an Innovative Technology contract from Vizient ® Inc. (“Vizient”), the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of BIASURGE by hospital experts who serve on one of Vizient's client-led councils, and it signifies to Vizient clients BIASURGE's unique qualities that potentially bring improvement to the healthcare industry.

Sanara MedTech (SMTI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd (“BMI”), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic ™ Synthetic Injectable Structural Bio-Adhesive (“OsStic”) to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration (“FDA”), to support reduction and provisional fixation treatment of the more than 100,000(1) peri-articular fractures occurring annually nationwide.

SMTI's surgical segment revenue grew 22% year-over-year in Q3 to $26.3 million. Surgical segment adjusted EBITDA was $4.9 million, at a margin of 18.6%. Following a strategic review, management has decided to discontinue the THP segment despite significant investments that were made.

ATLANTA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. (“Sanara” or “the Company”) (NASDAQ: SMTI) complied with federal securities laws. On November 11, 2025, Sanara announced that “the Company initiated a strategic realignment of its business, discontinuing operations of [Tissue Health Plus] to improve its operating efficiency and reallocate resources to its core surgical business.” Following this news, the price of the Company's stock dropped.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANARA MEDTECH INC. (SMTI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Novem.